Cardiovascular Diseases Clinical Trial
Official title:
Stroke Rehabilitation With Exoskeleton-assisted Gait: Clinical and Neuromuscular Outcomes.
Gait recovery is one of the main goals of post-stroke rehabilitation where robotic-assisted
practice has shown positive outcomes. However, literature lacks of clinical studies on
exoskeleton-supported gait rehabilitation. Recently, a wearable exoskeleton (Ekso™,
EksoBionics, USA) has been commercialized for re-enabling patients to stand and walk,
involving them directly in steps trigger through body weight balance. The main aim of this
study is to assess the clinical and neuromuscular effects of exoskeleton-based gait
rehabilitation in sub-acute and chronic stroke patients, compared to patients with similar
characteristics who will conduct a traditional over-ground gait training.
In this multicentric RCT, 162 stroke patients will be enrolled and randomly assigned to the
Experimental Group (EG) or to the Control Group (CG). Patients will conduct at least 12
one-hour-sessions (about 3 times/ week) of Ekso™ (EG) or traditional over-ground (CG) gait
rehabilitation. Clinical evaluations (lower limb Modified Ashworth Scale- MAS; Motricity
Index - MI; Trunk Control Test - TCT; Functional Ambulation Classification - FAC; 10-meter
walking test - 10mwt; 6-minute walking test - 6mwt; Walking Handicap Scale - WHS; Time Up and
Go - TUG) will be administered to patients at the beginning (T1) and at the end (T2) of the
training period. The primary outcome is the distance performed during the 6mwt. A follow up
study at 1 month (T3) and at 3 months (T4) after T2 will be conducted.
*Procedures During Screening Process:
This multicentric study will involve recruitment of individuals who have experienced a middle
to severe stroke as well as patients with similar neurological weakness from the inpatient
setting, outpatient clinics, as well as day rehabilitation sites through all the health
institutes participating to this study project. Members of the research teams will perform
the initial screening of potential subjects. These clinicians will determine study
eligibility based on the inclusion and exclusion criteria provided by Ekso Bionics in
accordance with the medical recommendations of Prof. Marco Franceschini.
Potential subjects will be asked questions regarding their medical history and current level
of function. If the subject meets the criteria, researchers will then provide the subject
with a consent form. The researchers will discuss the objectives, the study protocol, and the
risks and benefits to each subject. The subjects will be given time to review the form and
ask any questions about it.
Once each subject has provided informed consent, he or she will undergo a screening process
to assess the joint range of motion, and any spasticity present (via Modified Ashworth
Scale). These measures will be used to determine subject qualification based on inclusion and
exclusion criteria. Vital signs (including heart rate, blood pressure and oxygen saturation)
will be assessed at baseline, after each session, and during sessions as needed based on
subject's signs and symptoms. Oxygen saturation and heart rate will be monitored using a
pulse oximeter. Blood pressure will be assessed with a manual blood pressure cuff and
stethoscope.
Participants will be screened at the first therapy session (T1) and at the last one (T2).
Follow-up assessments will also take place at 1 month (T3) and 3 months (T4) after the end of
treatment.
*Procedures During Treatment: The enrolled stroke patients will be randomly assigned to the
Experimental Group (EG) or to the Control Group (CG). All patients will conduct gait therapy
for at least 12 (subacute patients) or 18 (chronic patients) one-hour-sessions (about 3
times/ week).
Experimental Group (EG): Exoskeleton-Assisted Over ground Gait Training Sessions will begin
with donning the Ekso device to ensure a proper fit. A physical therapist will check the
subject for proper alignment of joints with the device and check for areas of increased
pressure between the device and body. If necessary, additional padding will be added to
ensure safety and comfort or the device configuration will be modified. During the initial
sessions, skin checks will be occur more frequently at the end of each session to customize
well the padding. Moreover, the identification of the best exoskeleton settings for each
patient will be conducted for planning a customized and tailored robotic treatment.
During the treatment, the subject will be trained in interfacing with the exoskeleton Ekso
with optimal postural alignment, and weight shifting strategies. No strength is required from
the patient; only proper balance and weight shifts are required to achieve walking since
steps are triggered by the user's lateral weight shift. Enrolled patients will undergo 60
minute long sessions of gait training using the powered wearable exoskeleton. Patients will
conduct robotic training in conjunction with conventional physiotherapy training.
Control Group (CG): Traditional Over ground Gait Training The control group will perform 60
minute long sessions of Traditional Over ground Gait Training with a senior physiotherapist.
In the starting phase, the gait task can be facilitated by the physiotherapist or by using
aids, such as walkers, tripods etc.
Traditional Over ground Gait Training includes:
- Sit-to-Stand tasks
- Exercises for upright position control (right/left load shift): these tasks will allow
to include people who are unable to walk in the CG.
- In case of patients able to walk or once this turns possible, they will be trained to
re-learn a correct pattern of gait while walking over the ground.
CG patients will not use any other robots or treadmill for gait training.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Recruiting |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Recruiting |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Recruiting |
NCT02543996 -
Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)
|
||
Active, not recruiting |
NCT03603769 -
In Vitro And Ex Vivo Anti-Inflammatory Activities Of Salmon Polar Lipids
|
N/A | |
Not yet recruiting |
NCT03575650 -
Early Detection of Imaging-derived Subclinical Cardiac Injuries
|
||
Recruiting |
NCT03534908 -
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study
|
||
Completed |
NCT03807323 -
Tools for Lasting Lifestyle Changes
|
N/A | |
Enrolling by invitation |
NCT03271931 -
Active Choice in the EHR to Promote Statin Therapy
|
N/A | |
Recruiting |
NCT03413345 -
Effect of Rehabilitation on Ejection Fraction (FE) in Cardiopathic and Non Cardiopathic Patients Undergoing Major Orthopedic Surgery
|
N/A | |
Recruiting |
NCT03699293 -
NSAIDs vs. Coxibs in the Presence of Aspirin
|
Phase 4 | |
Active, not recruiting |
NCT03292029 -
Pilot Medical Evaluation of the T50 Test
|
N/A | |
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Safety and Efficacy of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Not yet recruiting |
NCT03659565 -
Increasing Caregiver and Patient Engagement Through PHR Use
|
N/A | |
Recruiting |
NCT02922088 -
EU Multicenter Registry to Assess Outcomes in CABG Patients: Treatment of Vascular Conduits With DuraGraft [VASC]
|
N/A | |
Recruiting |
NCT02890927 -
Geriatric-CO-mAnagement for Cardiology Patients in the Hospital
|
N/A | |
Active, not recruiting |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Completed |
NCT02986165 -
Effect of Ingesting a Tomato Pomace Extract on Platelet Aggregation
|
N/A |